thumb
November 22, 2021

Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease

Today, Biogen and Eisai announced that the Journal of the American Medical Association (JAMA) Neurology published a peer-reviewed paper about findings around amyloid-related imaging abnormalities (ARIA) in the Phase 3 trials of ADUHELM (aducanumab-avwa).

thumb
February 24, 2021

Life Science Cares and Biogen Foundation Help Launch Food For Free’s Just Eats Program

$170,000 grants will fill critical gap for 3,000 food insecure families in Greater Boston via Food For Free’s new grocery box program CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Life Science Cares Boston and the Biogen Foundation have teamed up as inaugural sponsors of Food For Free’s new

thumb
February 11, 2021

Biogen Announces the Expiration Date Results of Its Cash Tender Offer

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the expiration date results of its previously announced offer to purchase for cash (the “Cash Offer”) its outstanding 5.200% Senior Notes due 2045 (the “Notes”), totaling $1.75 billion in

thumb
February 11, 2021

Biogen Announces the Expiration Date Results of Its Private Exchange Offer

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the expiration date results of its previously announced private offer to exchange (the “Exchange Offer”) any and all of its outstanding 5.200% Senior Notes due 2045 (the “Old Notes”), totaling

thumb
February 11, 2021

Biogen and LabCentral Award Two Golden Tickets to Local and Innovative Science Startups

Golden Tickets winners Bolden Therapeutics and Seranova Bio will have access to a state-of-the-art lab facilities at LabCentral with mentorship and support from Biogen CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Biogen Inc.  (Nasdaq: BIIB) and LabCentral today announced Bolden Therapeutics

thumb
February 10, 2021

Biogen Announces the Pricing Terms of its Cash Tender Offer

CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the pricing terms of its previously announced offer to purchase for cash (the “Cash Offer”) its outstanding 5.200% Senior Notes due 2045 (the “Notes”), totaling $1.75 billion in aggregate

thumb
February 10, 2021

Biogen Announces the Pricing Terms of Its Private Exchange Offer

CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the pricing terms of its previously announced private offer to exchange (the “Exchange Offer”) any and all of its outstanding 5.200% Senior Notes due 2045 (the “Old Notes”), totaling $1.75

thumb
February 4, 2021

Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the commencement of an offer to purchase for cash (the “Cash Offer”) any and all of its outstanding 5.200% Senior Notes due 2045 (the “Notes”), totaling $1.75 billion in aggregate principal

thumb
February 4, 2021

Biogen Announces Private Exchange Offer for 5.200% Senior Notes Due 2045 Open to Certain Investors

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the commencement of a private offer to exchange (the “Exchange Offer”) any and all of its outstanding 5.200% Senior Notes due 2045 (the “Old Notes”), totaling $1.75 billion in aggregate

thumb
February 1, 2021

Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis

Intramuscular injection PLEGRIDY (peginterferon beta-1a) is now approved in the U.S. and the European Union, offering individuals with relapsing multiple sclerosis (MS) a treatment option with significantly reduced injection site reactions PLEGRIDY has a well-characterized safety and efficacy

thumb
January 29, 2021

Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab

The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is June 7, 2021 CAMBRIDGE, Mass. and TOKYO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has extended the review